Related Experiment Video
Updated: Jan 20, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
Taymeyah Al-Toubah1, Brian Morse2, Jonathan Strosberg1
1Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Background:
Patients with advanced lung neuroendocrine neoplasms (NENs) have few treatment options. Capecitabine and temozolomide have recently showed significant activity in patients with pancreatic neuroendocrine tumors (NETs), but data in lung NETs are limited.
Methods:
We retrospectively reviewed the records of patients treated at a large referral center to identify patients seen between January 2008 and September 2018 with metastatic lung NENs who received treatment with capecitabine and temozolomide (CAPTEM). Patients with small cell lung cancer were excluded. The primary endpoint was overall response rate per RECIST 1.1. Secondary endpoints included progression-free survival, overall survival, and toxicity.
Results:
Twenty patients were identified who received treatment with capecitabine and temozolomide. Fourteen (70%) had typical lung NETs, five had (25%) atypical carcinoids, and one (5%) had disease defined as a large-cell neuroendocrine carcinoma. Nineteen patients were evaluable for response. Six (30%) patients exhibited a best response of partial response per RECIST 1.1 criteria, 11 (55%) stable disease, and 2 (10%) progressive disease; objective response rate was 30%, and disease control rate was 85%. Eleven patients eventually progressed, only six of whom exhibited progression per RECIST 1.1 criteria. Median progression-free survival was 13 months (95% confidence interval [CI], 4.4-21.6 months). Median overall survival was 68 months (95% CI, 35.3-100.7 months). Toxicity profile was mild with mainly grade 1, expected toxicities. Six patients required dose reduction because of toxicity.
Conclusion:
The CAPTEM regimen is associated with a high response rate and a relatively tolerable toxicity profile in lung NENs. This regimen warrants further exploration in a prospective clinical trial.
Implications For Practice:
Patients with advanced lung neuroendocrine neoplasms have very few systemic treatment options. The capecitabine and temozolomide regimen has previously shown significant activity in patients with pancreatic neuroendocrine tumors (NETs) but has not been explored in metastatic lung NETs. This study showed that this regimen is associated with a high response rate (30%) and a relatively tolerable toxicity profile in this population.
Insights
The capecitabine and temozolomide (CAPTEM) regimen shows a 30% response rate in advanced lung neuroendocrine neoplasms (NENs). This treatment offers a tolerable option for patients with limited therapeutic choices.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Advanced lung neuroendocrine neoplasms (NENs) present limited therapeutic avenues.
- The capecitabine and temozolomide (CAPTEM) regimen has demonstrated efficacy in pancreatic neuroendocrine tumors (NETs).
- Data regarding CAPTEM's use in lung NETs remains scarce.
Purpose of the Study:
- To evaluate the efficacy and safety of the capecitabine and temozolomide (CAPTEM) regimen in patients with metastatic lung NENs.
- To determine the objective response rate (ORR) and disease control rate (DCR) of CAPTEM therapy.
- To assess progression-free survival (PFS), overall survival (OS), and toxicity associated with CAPTEM.
Main Methods:
- Retrospective review of patients with metastatic lung NENs treated with capecitabine and temozolomide (CAPTEM) between January 2008 and September 2018.
- Exclusion of small cell lung cancer patients.
- Evaluation of response based on RECIST 1.1 criteria, alongside assessment of PFS, OS, and toxicity.
Main Results:
- The study identified 20 patients treated with CAPTEM; 14 had typical lung NETs, 5 atypical carcinoids, and 1 large-cell neuroendocrine carcinoma.
- An objective response rate (ORR) of 30% and a disease control rate (DCR) of 85% were observed.
- Median progression-free survival (PFS) was 13 months, and median overall survival (OS) was 68 months, with a generally mild toxicity profile.
Conclusions:
- The capecitabine and temozolomide (CAPTEM) regimen demonstrates a high response rate and acceptable toxicity in advanced lung NENs.
- CAPTEM represents a promising treatment option for patients with lung NENs.
- Further investigation of the CAPTEM regimen in a prospective clinical trial is warranted.
Related Concept Videos
Lung Capacity
Extraction: Advanced Methods
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
Pleura of the Lungs
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques

